Effect of Tadalafil on prostate haemodynamics: Preliminary evaluation with contrast-enhanced US;Effetto del Tadalafil sull'emodinamica prostatica: valutazione preliminare con ecocontrastografia

Radiologia Medica

Volumn 114, Issue 7, 2009, Pages 1106-1114

  Bertolotto, M ^a   Trincia, E ^a   Zappetti, R ^a   Bernich, R ^a   Savoca, G ^b   Cova, M A ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b Ospedale Fondazione San Raffaele Giglio   (Italy)

Author keywords

Benign prostatic hyperplasia (BPH); Contrast enhanced ultrasound; Phosphodiesterase 5; Prostate; Tadalafil

Indexed keywords

ECHO CONTRAST MEDIUM; PHOSPHODIESTERASE V INHIBITOR; SONOVUE; TADALAFIL;

ADULT; AGED; ARTICLE; BLOOD FLOW; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; CONTRAST ENHANCED ULTRASONOGRAPHY; CONTRAST ENHANCEMENT; DRUG EFFECT; ECHOGRAPHY; ENZYME INHIBITION; ERECTILE DYSFUNCTION; HUMAN; IMAGING SYSTEM; LOWER URINARY TRACT SYMPTOM; MALE; PROSTATE; PROSTATE HYPERTROPHY; TRANSRECTAL ULTRASONOGRAPHY; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; CARBOLINES; CONTRAST MEDIA; HEMODYNAMICS; HUMANS; INFUSIONS, INTRALESIONAL; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PROSTATE; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 70450255080     PISSN: 00338362     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11547-009-0449-8     Document Type: Article

References (26)

1. C.S. Lin G. Lin Z.C. Xin 2006 Expression, distribution and regulation of phosphodiesterase 5 Curr Pharm Des 12 3439 3457 10.2174/138161206778343064 1:CAS:528:DC%2BD28XhtVGlt7%2FJ 17017938 (Pubitemid 44400482)
2. P. Stacey S. Rulten A. Dapling 1998 Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5) Biochem Biophys Res Commun 247 249 254 10.1006/bbrc.1998.8769 1:CAS:528:DyaK1cXkt1Skt7g%3D 9642111 (Pubitemid 28420808)
3. K. Loughney T.R. Hill V.A. Florio 1998 Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′- cyclic nucleotide phosphodiesterase Gene 216 139 147 10.1016/S0378-1119(98) 00303-5 1:CAS:528:DyaK1cXlvFSjt70%3D 9714779 (Pubitemid 28389111)
4. S.D. Rybalkin C. Yan K.E. Bornfeldt 2003 Cyclic GMP phosphodiesterases and regulation of smooth muscle function Circ Res 93 280 291 10.1161/01.RES.0000087541.15600.2B 1:CAS:528:DC%2BD3sXmt1OhsrY%3D 12933699 (Pubitemid 37048240)
5. M.C. Truss S. Uckert C.G. Stief 1996 Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization Urol Res 24 123 128 10.1007/BF00304074 1:CAS:528: DyaK28XltFWitrY%3D 8839478 (Pubitemid 26226247)
6. S. Uckert A. Kuthe U. Jonas 2001 Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate J Urol 166 2484 2490 10.1016/S0022-5347(05)65621-2 1:CAS:528: DC%2BD38XktFOm 11696815
7. P.I. Adolfsson C. Ahlstrand E. Varenhorst 2002 Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafil and papaverin generate inhibition Prostate 51 50 58 10.1002/pros.10077 1:CAS:528:DC%2BD38XjtlCit7Y%3D 11920958 (Pubitemid 34274860)
8. K.A. Lucas G.M. Pitari S. Kazerounian 2000 Guanylyl cyclases and signaling by cyclic GMP Pharmacol Rev 52 375 414 1:CAS:528:DC%2BD3cXntFCmsbg%3D 10977868
9. J.D. Corbin S.H. Francis D.J. Webb 2002 Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction Urology 60 4 11 10.1016/S0090-4295(02)01686-2 12414329 (Pubitemid 35300142)
10. K.E. Andersson C.R. Chapple K. Hofner 2002 Future drugs for the treatment of benign prostatic hyperplasia World J Urol 19 436 442 1:CAS:528: DC%2BD38XktlWntb4%3D 12022712
11. P. Sandner J. Hutter H. Tinel 2007 PDE5 inhibitors beyond erectile dysfunction Int J Impot Res 19 533 543 10.1038/sj.ijir.3901577 1:CAS:528:DC%2BD2sXht1Gls7bN 17625575 (Pubitemid 350059687)
12. S.J. Grimsley M.H. Khan G.E. Jones 2007 Mechanism of phosphodiesterase 5 inhibitor relief of prostatitis symptoms Med Hypotheses 69 25 26 10.1016/j.mehy.2006.11.040 1:CAS:528:DC%2BD2sXlt1Sju7g%3D 17300876 (Pubitemid 46686963)
13. K.E. Andersson S. Uckert C. Stief 2007 Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS Neurourol Urodyn 26 928 933 10.1002/nau.20485 1:CAS:528:DC%2BD2sXhtlSltLvN 17806124 (Pubitemid 47548230)
14. K.T. McVary C.G. Roehrborn J.C. Kaminetsky 2007 Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia J Urol 177 1401 1407 10.1016/j.juro.2006.11.037 1:CAS:528:DC%2BD2sXksVantL8%3D 17382741 (Pubitemid 46435965)
15. H. Tinel B. Stelte-Ludwig J. Hutter 2006 Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms BJU Int 98 1259 1263 10.1111/j.1464-410X.2006. 06501.x 1:CAS:528:DC%2BD2sXktlakuw%3D%3D 16956354 (Pubitemid 44721238)
16. E.S. Waldkirch S. Uckert K. Langnase 2007 Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue Eur Urol 52 495 501 10.1016/j.eururo.2007.02.004 1:CAS:528:DC%2BD2sXpsFKlur8%3D 17329019 (Pubitemid 46963439)
17. K. Wei A.R. Jayaweera S. Firoozan 1998 Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion Circulation 97 473 483 1:STN:280:DyaK1c7ktVKrtw%3D%3D 9490243
18. M. Bertolotto G. Pozzato L.S. Croce 2006 Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: preliminary results Invest Radiol 41 15 21 10.1097/01.rli.0000188363.93670.45 1:CAS:528: DC%2BD2MXhtlSqu7%2FM 16355035 (Pubitemid 44378274)
19. K. Wei E. Le J.P. Bin 2001 Quantification of renal blood flow with contrast-enhanced ultrasound J Am Coll Cardiol 37 1135 1140 10.1016/S0735- 1097(00)01210-9 1:STN:280:DC%2BD3M7mtlKrtw%3D%3D 11263620 (Pubitemid 32217618)
20. G. Seidel L. Claassen K. Meyer 2001 Evaluation of blood flow in the cerebral microcirculation: analysis of the refill kinetics during ultrasound contrast agent infusion Ultrasound Med Biol 27 1059 1064 10.1016/S0301-5629(01) 00416-1 1:STN:280:DC%2BD3Mvos1antw%3D%3D 11527592 (Pubitemid 32807728)
21. I. Iordanescu C. Becker B. Zetter 2002 Tumor vascularity: evaluation in a murine model with contrast-enhanced color Doppler US effect of angiogenesis inhibitors Radiology 222 460 467 10.1148/radiol.2222010660 11818614
22. S. Siracusano M. Bertolotto A. Cucchi 2006 Application of ultrasound contrast agents for the characterization of female urethral vascularization in healthy pre- and postmenopausal volunteers: preliminary report Eur Urol 50 1316 1322 10.1016/j.eururo.2006.05.044 16831513 (Pubitemid 44692927)
23. L. Rubaltelli S. Corradin A. Dorigo 2007 Automated quantitative evaluation of lymph node perfusion on contrast-enhanced sonography AJR Am J Roentgenol 188 977 983 10.2214/AJR.06.0562 17377033 (Pubitemid 46496929)
24. M. Mitterberger G.M. Pinggera W. Horninger 2007 Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score J Urol 178 464 468 10.1016/j.juro.2007.03.107 1:STN:280:DC%2BD2svgvVSjuw%3D%3D 17561137 (Pubitemid 47030488)
25. M. Mitterberger A. Pelzer D. Colleselli 2007 Contrast-enhanced ultrasound for diagnosis of prostate cancer and kidney lesions Eur J Radiol 64 231 238 10.1016/j.ejrad.2007.07.027 17881175 (Pubitemid 47588759)
26. T.E. Goossen J.J. de la Rosette C.A. Hulsbergen-van de Kaa 2003 The value of dynamic contrast enhanced power Doppler ultrasound imaging in the localization of prostate cancer Eur Urol 43 124 131 10.1016/S0302-2838(02)00582- 1 12565769 (Pubitemid 36221964)